HR Notices From May 25
VandenBoom Named Director of Automotive Marketing at Coherix: Rick VandenBoom has been named director of automotive marketing at Ann Arbor- based Coherix, the developer of high-speed, high-definition 3D visualization systems to improve the quality and reliability of automotive and semiconductor manufacturing processes. VandenBoom began his career in electrical engineering at Control Engineering in Pellston and went on to hold positions as an application engineer and project manager at SI Handling Systems in Rochester and ABB Flexible Automation in Auburn Hills. He joined Perceptron in Plymouth as an account manager for the company's Chrysler account in 1995 and also has held senior management positions at Michigan-based CogniTens in Wixom and FriCSo in Farmington Hills. VandenBoom holds a degree in electronics engineering technology from the National Institute of Technology. Based on research conducted at the University of Michigan, Coherix technology makes it possible for original equipment manufacturers to visually detect for the first time variations in component surface quality critical to product performance. The company's high-speed, non- contact ShaPix systems are designed to improve quality, lower costs, shorten new-product development time and increase customer satisfaction. Coherix products are in operation around the world at companies such as Intel, Amkor, Bosch, BorgWarner, Ford, Honda, MAG, Chrysler, General Motors, Micron, Infineon, Volvo Technology Transfer and TRW. More information is available at www.coherix.com.
NanoBio Appoints Ulrich to Board: Ann Arbor-based NanoBio Corp. announced the appointment of Peter Ulrich, co-founder of TargeGen, to its Board of Directors. Ulrich most recently served as President and CEO of TargeGen, co-founding the company and leading it from inception through exit in a $560 million acquisition by Sanofi-Aventis. TargeGen developed small molecule kinase inhibitors for oncology, inflammatory disease, eye disease, myeloproliferative disease, leukemia and other hematological disorders. Ulrich has more than 35 years of executive experience in biotechnology and healthcare, with more than 20 years of CEO tenure. Prior to co- founding TargeGen, Ulrich was president and CEO of Avia Technology Partners, a biotechnology-oriented, strategic, consulting firm. Ulrich has held positions with Baxter Health Care, La Jolla Pharmaceutical Company, MedClone Inc., NeuroVir Therapeutics Inc., LipoGen, Inc., Biotx, Analytical Luminescence Laboratory and The University of Alabama at Birmingham Research Foundation. Ulrich's entrepreneurial achievements include a consistent track record of success with early stage life sciences companies, the ability to secure over $150M in private equity financing from venture capital sources and recognition by Ernst & Young as an Entrepreneur of the Year. NanoBio is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat technology platform. The company's lead product candidates are treatments for herpes labialis (better known as cold sores, licensed to GSK in the U.S. and Canada), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. More at www.nanobio.com.
